Ex-NIH boss is new R&D head at Sanofi-Aventis
This article was originally published in Scrip
Executive Summary
Dr Elias Zerhouni has been appointed president of global R&D at Sanofi-Aventis, which covers medicines and vaccines, effective 1 January. Dr Marc Cluzel is resigning as executive vice president of R&D at the company but will continue in an advisory capacity for the time-being. Dr Zerhouni has been scientific advisor to CEO Christopher Viehbacher since February 2009. In October 2008 he stepped down as the director of the US NIH after more than six years in the position. He is currently professor of radiology and biomedical engineering at the John Hopkins University and Hospital (US).
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.